Publications by authors named "Fynn Gurski"
Article Synopsis
- The FGF, VEGFR-2, and CSF1R signaling pathways are crucial in the development of multiple sclerosis (MS), and inhibiting FGFR with infigratinib showed a 40% prevention of severe symptoms in a mouse model.
- Fexagratinib, which inhibits multiple kinases, demonstrated significant reductions in inflammation and neurodegeneration, with a 66.7% to 84.6% prevention of severe episodes in mice depending on the dosage used.
- The study suggests that using a low, well-tolerated dose of fexagratinib in humans could be effective in slowing down MS progression and enhancing remyelination.
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS). MS commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs significantly contribute to clinical disability, and symptoms such as tremor, ataxia, and dysarthria are difficult to treat.
View Article and Find Full Text PDF